Categories: News

CORRECTION: Orion Corporation: Managers’ transactions – Liisa Hurme

ORION CORPORATION MANAGERS’ TRANSACTIONS 23 JULY 2021 at 15.30 EEST

Orion Oyj: Correction of the content of the Managers’s transaction notification

CORRECTION: Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation is correcting its stock exchange release from 23 July 2021 at 15.00 EEST. The present release is based on the amended Managers’ transactions notification received by the company. In the initial notification, the box “Legal person” was erroneously ticked. Additionally, the amended notification specifies the dates of the transactions.

The following are the contents of the amended Managerstransactions notification:

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________

Person subject to the notification requirement
Name: Aino Anna Liisa Hurme
Position: Other senior manager
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745

Notification type: AMENDMENT
Reference number: 74370029VAHCXDR7B745_20210723122117_6
Amendment comment:
Amendment to the initial notification where “Legal person” was erroneously ticked. Also added another page for transaction carried out on 23 July 2021.
____________________________________________

Transaction date: 2021-07-22
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 1,000 Unit price: 35.01 EUR
(2): Volume: 1,000 Unit price: 35.008 EUR
(3): Volume: 5,000 Unit price: 35.1 EUR

Aggregated transactions
(3): Volume: 7,000 Volume weighted average price: 35.074 EUR
____________________________________________

Transaction date: 2021-07-23
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 5,700 Unit price: 35.3 EUR

Aggregated transactions
(1): Volume: 5,700 Volume weighted average price: 35.3 EUR

Orion Corporation

Timo Lappalainen

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Staff

Recent Posts

Med Holdings Group, Inc. (FKA Yuka Group, Inc.) Announces Acquisition Of Medsmart Wellness Centers, Inc.

DENVER, CO / ACCESSWIRE / March 22, 2024 / (OTC Pink:YUKA) Med Holdings Group, Inc.…

1 hour ago

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

4 hours ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

4 hours ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

4 hours ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

4 hours ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

5 hours ago